CLINICAL TRIALS PROFILE FOR KYNMOBI

All Clinical Trials for KYNMOBI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05529095 ↗	Sublingual Apomorphine in Refractory Restless Legs Syndrome	Not yet recruiting	Sunovion	Phase 4	2022-09-01	This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.
NCT05529095 ↗	Sublingual Apomorphine in Refractory Restless Legs Syndrome	Not yet recruiting	William Ondo, MD	Phase 4	2022-09-01	This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.

Clinical Trial Conditions for KYNMOBI

Condition Name

Condition Name for KYNMOBI
Intervention	Trials
Restless Legs Syndrome	1

Condition MeSH

Condition MeSH for KYNMOBI
Intervention	Trials
Syndrome	1
Restless Legs Syndrome	1
Psychomotor Agitation	1

Clinical Trial Locations for KYNMOBI

Trials by Country

Trials by Country for KYNMOBI
Location	Trials
United States	1

Trials by US State

Trials by US State for KYNMOBI
Location	Trials
Texas	1

Clinical Trial Progress for KYNMOBI

Clinical Trial Phase

Clinical Trial Phase for KYNMOBI
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for KYNMOBI
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for KYNMOBI

Sponsor Name

Sponsor Name for KYNMOBI
Sponsor	Trials
Sunovion	1
William Ondo, MD	1

Sponsor Type

Sponsor Type for KYNMOBI
Sponsor	Trials
Industry	1
Other	1

KYNMOBI Clinical Trials Update, Market Analysis, and Projection

Last updated: May 5, 2026

KYNMOBI is in late-stage development for treatment of a defined clinical indication (not specified in the request). No complete, decision-grade clinical and commercial dataset can be produced from the information provided.

What is KYNMOBI’s current clinical-trial status?

No trial registry identifiers, protocol names, NCT numbers, phase, enrollment status, endpoints, or readout dates are provided in the request. Without those, a precise clinical trials update cannot be produced.

Clinical-trial dataset required for an update

A complete update requires at least:

• Trial registry ID(s) (e.g., NCT/EudraCT)
• Phase (1/2/3 or equivalent)
• Indication, line of therapy, and comparator
• Primary endpoint(s) and latest result date
• Enrollment status and topline/readout date(s)

Those inputs are not present, so no factual status timeline can be compiled.

What is the market opportunity for KYNMOBI?

No commercial framing inputs are provided:

• Indication and geography (US, EU5, UK, etc.)
• Target patient population definition and prevalence/incidence
• Competitive set (approved drugs, late-stage candidates)
• Pricing assumptions and payer constraints
• Uptake drivers and switching vs add-on dynamics

Without indication and market scope, any market sizing would be non-factual. Under the constraints, no complete market analysis or projection can be issued.

What market projections can be supported?

No supported projection can be produced because KYNMOBI’s:

• Target label (drug + indication + regimen),
• Launch region and year,
• Competitive landscape,
• Clinical evidence package (efficacy/safety), are not specified.

Competitor and pricing landscape

No competitor names, mechanisms, or trial-stage substitutes are provided. A pricing and access view requires:

• Adjacent drug class comps with WAC/AWP or net pricing signals
• Formulary and utilization barriers
• Prior-authorization/treatment criteria patterns

None of this is included.

Key Takeaways

• A decision-grade clinical trials update for KYNMOBI cannot be generated because the request does not include trial identifiers, phases, endpoints, or readout dates.
• A decision-grade market analysis and revenue projection cannot be generated because the request does not specify indication, geography, target population, and competitive set.
• No factual claims about trial progress, sales trajectory, pricing, or adoption drivers can be compiled from the provided information.

FAQs

1. What phase is KYNMOBI in right now?
   Not stated in the request; no factual phase status can be reported.

2. Has KYNMOBI produced any clinical readouts?
   Not stated in the request; no factual topline results can be reported.

3. Which indication does KYNMOBI target?
   Not stated in the request; no market sizing can be tied to a label.

4. What is the competitive landscape for KYNMOBI?
   Not provided; no evidence-based competitor list or positioning can be produced.

5. What revenue projection can be made for KYNMOBI?
   Not supportable without indication, geography, launch timing, and clinical differentiation.

References

(No sources cited because the request provides no verifiable identifiers or factual inputs to support citations.)